We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Liquid-Ready QC Solution for POC Urinalysis Instruments Helps Labs Streamline Daily Operations

By LabMedica International staff writers
Posted on 23 Jan 2023
Print article
Image: Chek-Stix UA Diptube Liquid QC (Photo courtesy of Siemens)
Image: Chek-Stix UA Diptube Liquid QC (Photo courtesy of Siemens)

Healthcare and laboratory professionals need to ensure consistent and accurate results. Now, a liquid-ready urinalysis solution for use with point-of-care urinalysis instruments and reagents, including 12 parameters and hCG, aims to help labs streamline their daily operations.

Siemens Healthineers (Erlangen, Germany) has launched Chek-Stix Liquid Quality Control solutions - the latest innovation in its urinalysis portfolio. Chek-Stix UA Diptube Liquid QC contains both Level 1 (negative for all chemistry parameters and positive for hCG) and Level 2 (positive for all chemistry parameters and negative for hCG), packaged in one box. Both Level 1 and Level 2 diptube controls are ready-to-use liquid quality controls for use with the CLINITEK Status+ Analyzer, CLINITEK Advantus Analyzer, and visual-read urine strips.

Liquid-ready solution means less time spent on prepping quality control solution and more time on running patient samples. The product is barcode-enabled for quick, accurate data input and supports Siemens’ broad urine chemistry parameter menu. Validated for use with all Siemens’ urinalysis devices and reagents, the product has a shelf life of 22 months from the manufacture date.

Related Links:
Siemens Healthineers

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.